Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 429

1.

The Coagulation Factors Fibrinogen, Thrombin, and Factor XII in Inflammatory Disorders-A Systematic Review.

Göbel K, Eichler S, Wiendl H, Chavakis T, Kleinschnitz C, Meuth SG.

Front Immunol. 2018 Jul 26;9:1731. doi: 10.3389/fimmu.2018.01731. eCollection 2018.

2.

Discriminative power of intra-retinal layers in early multiple sclerosis using 3D OCT imaging.

Seitz CB, Droby A, Zaubitzer L, Krämer J, Paradis M, Klotz L, Wiendl H, Groppa S, Meuth SG, Zipp F, Fleischer V.

J Neurol. 2018 Aug 2. doi: 10.1007/s00415-018-8988-3. [Epub ahead of print]

PMID:
30073502
3.

Nur77 serves as a molecular brake of the metabolic switch during T cell activation to restrict autoimmunity.

Liebmann M, Hucke S, Koch K, Eschborn M, Ghelman J, Chasan AI, Glander S, Schädlich M, Kuhlencord M, Daber NM, Eveslage M, Beyer M, Dietrich M, Albrecht P, Stoll M, Busch KB, Wiendl H, Roth J, Kuhlmann T, Klotz L.

Proc Natl Acad Sci U S A. 2018 Aug 2. pii: 201721049. doi: 10.1073/pnas.1721049115. [Epub ahead of print]

PMID:
30072431
4.

Immune Cell Profiling During Switching from Natalizumab to Fingolimod Reveals Differential Effects on Systemic Immune-Regulatory Networks and on Trafficking of Non-T Cell Populations into the Cerebrospinal Fluid-Results from the ToFingo Successor Study.

Lohmann L, Janoschka C, Schulte-Mecklenbeck A, Klinsing S, Kirstein L, Hanning U, Wirth T, Schneider-Hohendorf T, Schwab N, Gross CC, Eveslage M, Meuth SG, Wiendl H, Klotz L.

Front Immunol. 2018 Jul 9;9:1560. doi: 10.3389/fimmu.2018.01560. eCollection 2018.

5.

Impairment of frequency-specific responses associated with altered electrical activity patterns in auditory thalamus following focal and general demyelination.

Narayanan V, Cerina M, Göbel K, Meuth P, Herrmann AM, Fernandez-Orth J, Stangel M, Gudi V, Skripuletz T, Daldrup T, Lesting J, Schiffler P, Wiendl H, Seidenbecher T, Meuth SG, Budde T, Pape HC.

Exp Neurol. 2018 Jul 23;309:54-66. doi: 10.1016/j.expneurol.2018.07.010. [Epub ahead of print]

PMID:
30048715
6.

Primary angiitis of the central nervous system: diagnosis and treatment.

Beuker C, Schmidt A, Strunk D, Sporns PB, Wiendl H, Meuth SG, Minnerup J.

Ther Adv Neurol Disord. 2018 Jul 9;11:1756286418785071. doi: 10.1177/1756286418785071. eCollection 2018. Review.

7.

Apraxia profiles-A single cognitive marker to discriminate all variants of frontotemporal lobar degeneration and Alzheimer's disease.

Johnen A, Reul S, Wiendl H, Meuth SG, Duning T.

Alzheimers Dement (Amst). 2018 May 16;10:363-371. doi: 10.1016/j.dadm.2018.04.002. eCollection 2018.

8.

Onconeural antigen spreading in paraneoplastic neurological disease due to small cell lung cancer.

Dik A, Strippel C, Mönig C, Golombeck KS, Schulte-Mecklenbeck A, Wiendl H, Meuth SG, Johnen A, Gross CC, Melzer N.

Oxf Med Case Reports. 2018 Jul 9;2018(7):omy034. doi: 10.1093/omcr/omy034. eCollection 2018 Jul.

9.

Immune cell profiling in the cerebrospinal fluid of patients with primary angiitis of the central nervous system reflects the heterogeneity of the disease.

Strunk D, Schulte-Mecklenbeck A, Golombeck KS, Meyer Zu Hörste G, Melzer N, Beuker C, Schmidt A, Wiendl H, Meuth SG, Gross CC, Minnerup J.

J Neuroimmunol. 2018 Aug 15;321:109-116. doi: 10.1016/j.jneuroim.2018.06.004. Epub 2018 Jun 7.

PMID:
29957380
10.

Amygdala enlargement and emotional responses in (autoimmune) temporal lobe epilepsy.

Holtmann O, Schlossmacher I, Moenig C, Johnen A, Rutter LM, Tenberge JG, Schiffler P, Everding J, Golombeck KS, Strippel C, Dik A, Schwindt W, Wiendl H, Meuth SG, Bruchmann M, Melzer N, Straube T.

Sci Rep. 2018 Jun 22;8(1):9561. doi: 10.1038/s41598-018-27914-z.

11.

Cerebrospinal Fluid Concentrations of Neuronal Proteins Are Reduced in Primary Angiitis of the Central Nervous System.

Ruland T, Wolbert J, Gottschalk MG, König S, Schulte-Mecklenbeck A, Minnerup J, Meuth SG, Groß CC, Wiendl H, Meyer Zu Hörste G.

Front Neurol. 2018 Jun 5;9:407. doi: 10.3389/fneur.2018.00407. eCollection 2018.

12.

DNA methylation as a mediator of HLA-DRB1*15:01 and a protective variant in multiple sclerosis.

Kular L, Liu Y, Ruhrmann S, Zheleznyakova G, Marabita F, Gomez-Cabrero D, James T, Ewing E, Lindén M, Górnikiewicz B, Aeinehband S, Stridh P, Link J, Andlauer TFM, Gasperi C, Wiendl H, Zipp F, Gold R, Tackenberg B, Weber F, Hemmer B, Strauch K, Heilmann-Heimbach S, Rawal R, Schminke U, Schmidt CO, Kacprowski T, Franke A, Laudes M, Dilthey AT, Celius EG, Søndergaard HB, Tegnér J, Harbo HF, Oturai AB, Olafsson S, Eggertsson HP, Halldorsson BV, Hjaltason H, Olafsson E, Jonsdottir I, Stefansson K, Olsson T, Piehl F, Ekström TJ, Kockum I, Feinberg AP, Jagodic M.

Nat Commun. 2018 Jun 19;9(1):2397. doi: 10.1038/s41467-018-04732-5.

13.

A Novel PKD1 Mutation Associated With Autosomal Dominant Kidney Disease and Cerebral Cavernous Malformation.

Thomas C, Zühlsdorf A, Hörtnagel K, Mulahasanovic L, Grauer OM, Kümpers P, Wiendl H, Meuth SG.

Front Neurol. 2018 May 25;9:383. doi: 10.3389/fneur.2018.00383. eCollection 2018.

14.

Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting.

Trojano M, Butzkueven H, Kappos L, Wiendl H, Spelman T, Pellegrini F, Chen Y, Dong Q, Koendgen H, Belachew S; Tysabri® Observational Program (TOP) Investigators.

Mult Scler Relat Disord. 2018 May 2;24:11-19. doi: 10.1016/j.msard.2018.04.020. [Epub ahead of print]

15.

Immunophenotyping of cerebrospinal fluid cells by Chipcytometry.

Hümmert MW, Alvermann S, Gingele S, Gross CC, Wiendl H, Mirenska A, Hennig C, Stangel M.

J Neuroinflammation. 2018 May 25;15(1):160. doi: 10.1186/s12974-018-1176-7.

16.

Does the environment influence multiple sclerosis pathogenesis via UVB light and/or induction of vitamin D?

Breuer J, Loser K, Mykicki N, Wiendl H, Schwab N.

J Neuroimmunol. 2018 May 18. pii: S0165-5728(17)30478-2. doi: 10.1016/j.jneuroim.2018.05.006. [Epub ahead of print] Review.

PMID:
29793727
17.

Protective potential of dimethyl fumarate in a mouse model of thalamocortical demyelination.

Cerina M, Narayanan V, Delank A, Meuth P, Graebenitz S, Göbel K, Herrmann AM, Albrecht S, Daldrup T, Seidenbecher T, Gorji A, Kuhlmann T, Wiendl H, Kleinschnitz C, Speckmann EJ, Pape HC, Meuth SG, Budde T.

Brain Struct Funct. 2018 May 9. doi: 10.1007/s00429-018-1680-7. [Epub ahead of print]

PMID:
29744572
18.

Time-resolved transcriptome and proteome landscape of human regulatory T cell (Treg) differentiation reveals novel regulators of FOXP3.

Schmidt A, Marabita F, Kiani NA, Gross CC, Johansson HJ, Éliás S, Rautio S, Eriksson M, Fernandes SJ, Silberberg G, Ullah U, Bhatia U, Lähdesmäki H, Lehtiö J, Gomez-Cabrero D, Wiendl H, Lahesmaa R, Tegnér J.

BMC Biol. 2018 May 7;16(1):47. doi: 10.1186/s12915-018-0518-3.

19.

Defining mechanisms of neural plasticity after brainstem ischemia in rats.

Minnerup J, Strecker JK, Wachsmuth L, Hoppen M, Schmidt A, Hermann DM, Wiendl H, Meuth S, Faber C, Diederich K, Schäbitz WR.

Ann Neurol. 2018 May;83(5):1003-1015. doi: 10.1002/ana.25238. Epub 2018 May 11.

PMID:
29665155
20.

Mechanisms underlying lesion development and lesion distribution in CNS autoimmunity.

Lindner M, Klotz L, Wiendl H.

J Neurochem. 2018 Mar 25. doi: 10.1111/jnc.14339. [Epub ahead of print] Review.

PMID:
29574788
21.

Association of smoking but not HLA-DRB1*15:01, APOE or body mass index with brain atrophy in early multiple sclerosis.

Graetz C, Gröger A, Luessi F, Salmen A, Zöller D, Schultz J, Siller N, Fleischer V, Bellenberg B, Berthele A, Biberacher V, Havla J, Hecker M, Hohlfeld R, Infante-Duarte C, Kirschke JS, Kümpfel T, Linker R, Paul F, Pfeuffer S, Sämann P, Toenges G, Weber F, Zettl UK, Jahn-Eimermacher A, Antony G, Groppa S, Wiendl H, Hemmer B, Mühlau M, Lukas C, Gold R, Lill CM, Zipp F.

Mult Scler. 2018 Mar 1:1352458518763541. doi: 10.1177/1352458518763541. [Epub ahead of print]

PMID:
29532745
22.

Skeletal muscle cells actively shape (auto)immune responses.

Afzali AM, Müntefering T, Wiendl H, Meuth SG, Ruck T.

Autoimmun Rev. 2018 May;17(5):518-529. doi: 10.1016/j.autrev.2017.12.005. Epub 2018 Mar 9. Review.

PMID:
29526638
23.

Treatment choices and neuropsychological symptoms of a large cohort of early MS.

von Bismarck O, Dankowski T, Ambrosius B, Hessler N, Antony G, Ziegler A, Hoshi MM, Aly L, Luessi F, Groppa S, Klotz L, Meuth SG, Tackenberg B, Stoppe M, Then Bergh F, Tumani H, Kümpfel T, Stangel M, Heesen C, Wildemann B, Paul F, Bayas A, Warnke C, Weber F, Linker RA, Ziemann U, Zettl UK, Zipp F, Wiendl H, Hemmer B, Gold R, Salmen A.

Neurol Neuroimmunol Neuroinflamm. 2018 Mar 1;5(3):e446. doi: 10.1212/NXI.0000000000000446. eCollection 2018 May.

24.

Transcriptional Repressor HIC1 Contributes to Suppressive Function of Human Induced Regulatory T Cells.

Ubaid Ullah, Andrabi SBA, Tripathi SK, Dirasantha O, Kanduri K, Rautio S, Gross CC, Lehtimäki S, Bala K, Tuomisto J, Bhatia U, Chakroborty D, Elo LL, Lähdesmäki H, Wiendl H, Rasool O, Lahesmaa R.

Cell Rep. 2018 Feb 20;22(8):2094-2106. doi: 10.1016/j.celrep.2018.01.070.

25.

Sex bias in MHC I-associated shaping of the adaptive immune system.

Schneider-Hohendorf T, Görlich D, Savola P, Kelkka T, Mustjoki S, Gross CC, Owens GC, Klotz L, Dornmair K, Wiendl H, Schwab N.

Proc Natl Acad Sci U S A. 2018 Feb 27;115(9):2168-2173. doi: 10.1073/pnas.1716146115. Epub 2018 Feb 12.

PMID:
29440397
26.

Alemtuzumab Improves Cognitive Processing Speed in Active Multiple Sclerosis-A Longitudinal Observational Study.

Riepl E, Pfeuffer S, Ruck T, Lohmann H, Wiendl H, Meuth SG, Johnen A.

Front Neurol. 2018 Jan 16;8:730. doi: 10.3389/fneur.2017.00730. eCollection 2017.

27.

ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis.

Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, Clanet M, Comi G, Derfuss T, Fazekas F, Hartung HP, Havrdova E, Hemmer B, Kappos L, Liblau R, Lubetzki C, Marcus E, Miller DH, Olsson T, Pilling S, Selmaj K, Siva A, Sorensen PS, Sormani MP, Thalheim C, Wiendl H, Zipp F.

Mult Scler. 2018 Feb;24(2):96-120. doi: 10.1177/1352458517751049. Epub 2018 Jan 20.

PMID:
29353550
28.

ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis.

Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, Clanet M, Comi G, Derfuss T, Fazekas F, Hartung HP, Havrdova E, Hemmer B, Kappos L, Liblau R, Lubetzki C, Marcus E, Miller DH, Olsson T, Pilling S, Selmaj K, Siva A, Sorensen PS, Sormani MP, Thalheim C, Wiendl H, Zipp F.

Eur J Neurol. 2018 Feb;25(2):215-237. doi: 10.1111/ene.13536. Epub 2018 Jan 19. Erratum in: Eur J Neurol. 2018 Mar;25(3):605.

PMID:
29352526
29.

Defining response profiles after alemtuzumab: Rare paradoxical disease exacerbation.

Wiendl H, Calabresi PA, Meuth SG.

Neurology. 2018 Feb 13;90(7):309-311. doi: 10.1212/WNL.0000000000004969. Epub 2018 Jan 19. No abstract available.

PMID:
29352097
30.

Infectious risk stratification in multiple sclerosis patients receiving immunotherapy.

Graf J, Leussink VI, Dehmel T, Ringelstein M, Goebels N, Adams O, MacKenzie CR, Warnke C, Feldt T, Lammerskitten A, Klotz L, Meuth S, Wiendl H, Hartung HP, Aktas O, Albrecht P.

Ann Clin Transl Neurol. 2017 Nov 24;4(12):909-914. doi: 10.1002/acn3.491. eCollection 2017 Dec.

31.

Novel pathomechanisms in inflammatory neuropathies.

Schafflick D, Kieseier BC, Wiendl H, Meyer Zu Horste G.

J Neuroinflammation. 2017 Nov 28;14(1):232. doi: 10.1186/s12974-017-1001-8. Review.

32.

NMDAR encephalitis: passive transfer from man to mouse by a recombinant antibody.

Malviya M, Barman S, Golombeck KS, Planagumà J, Mannara F, Strutz-Seebohm N, Wrzos C, Demir F, Baksmeier C, Steckel J, Falk KK, Gross CC, Kovac S, Bönte K, Johnen A, Wandinger KP, Martín-García E, Becker AJ, Elger CE, Klöcker N, Wiendl H, Meuth SG, Hartung HP, Seebohm G, Leypoldt F, Maldonado R, Stadelmann C, Dalmau J, Melzer N, Goebels N.

Ann Clin Transl Neurol. 2017 Oct 3;4(11):768-783. doi: 10.1002/acn3.444. eCollection 2017 Nov.

33.

Defective synaptic transmission causes disease signs in a mouse model of juvenile neuronal ceroid lipofuscinosis.

Grünewald B, Lange MD, Werner C, O'Leary A, Weishaupt A, Popp S, Pearce DA, Wiendl H, Reif A, Pape HC, Toyka KV, Sommer C, Geis C.

Elife. 2017 Nov 14;6. pii: e28685. doi: 10.7554/eLife.28685.

34.

Relevance of raised cerebrospinal fluid monocyte levels in patients with frontotemporal dementia.

Pawlowski M, Lueg G, Gross CC, Johnen A, Krämer J, Weckesser M, Wiendl H, Meuth SG, Duning T.

Neurobiol Aging. 2018 Feb;62:45-52. doi: 10.1016/j.neurobiolaging.2017.09.032. Epub 2017 Oct 13.

PMID:
29107846
35.

Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis.

Rose JW, Giovannoni G, Wiendl H, Gold R, Havrdová E, Kappos L, Selmaj KW, Zhao J, Riester K, Tsao LC, Greenberg SJ.

Mult Scler Relat Disord. 2017 Oct;17:32-40. doi: 10.1016/j.msard.2017.06.006. Epub 2017 Jun 19.

PMID:
29055471
36.

An Enigmatic Case of Acute Mercury Poisoning: Clinical, Immunological Findings and Platelet Function.

Kleffner I, Eichler S, Ruck T, Schüngel L, Pfeuffer S, Polzer P, Dittrich R, Dziewas R, Gross CC, Göbel K, Wiendl H, Kehrel BE, Meuth SG.

Front Neurol. 2017 Sep 28;8:517. doi: 10.3389/fneur.2017.00517. eCollection 2017.

37.

Rivaroxaban ameliorates disease course in an animal model of multiple sclerosis.

Merker M, Eichler S, Herrmann AM, Wiendl H, Kleinschnitz C, Göbel K, Meuth SG.

J Neuroimmunol. 2017 Dec 15;313:125-128. doi: 10.1016/j.jneuroim.2017.08.013. Epub 2017 Sep 21.

PMID:
28992973
38.

Efficacy of daclizumab beta versus intramuscular interferon beta-1a on disability progression across patient demographic and disease activity subgroups in DECIDE.

Cohan S, Kappos L, Giovannoni G, Wiendl H, Selmaj K, Havrdová EK, Rose J, Greenberg S, Phillips G, Ma W, Wang P, Lima G, Sabatella G.

Mult Scler. 2017 Oct 1:1352458517735190. doi: 10.1177/1352458517735190. [Epub ahead of print]

PMID:
28984179
39.

Dual action by fumaric acid esters synergistically reduces adhesion to human endothelium.

Breuer J, Herich S, Schneider-Hohendorf T, Chasan AI, Wettschureck N, Gross CC, Loser K, Zarbock A, Roth J, Klotz L, Wiendl H, Schwab N.

Mult Scler. 2017 Oct 1:1352458517735189. doi: 10.1177/1352458517735189. [Epub ahead of print]

PMID:
28984166
40.

Liver X receptor activation promotes differentiation of regulatory T cells.

Herold M, Breuer J, Hucke S, Knolle P, Schwab N, Wiendl H, Klotz L.

PLoS One. 2017 Sep 19;12(9):e0184985. doi: 10.1371/journal.pone.0184985. eCollection 2017.

41.

Circulating lymphocyte levels and relationship with infection status in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta.

Giovannoni G, Wiendl H, Turner B, Umans K, Mokliatchouk O, Castro-Borrero W, Greenberg SJ, McCroskery P, Giannattasio G.

Mult Scler. 2017 Sep 1:1352458517729464. doi: 10.1177/1352458517729464. [Epub ahead of print]

PMID:
28914581
42.

Benefit-Risk Profile of Sphingosine-1-Phosphate Receptor Modulators in Relapsing and Secondary Progressive Multiple Sclerosis.

Comi G, Hartung HP, Bakshi R, Williams IM, Wiendl H.

Drugs. 2017 Oct;77(16):1755-1768. doi: 10.1007/s40265-017-0814-1.

43.

Distinct cognitive impairments in different disease courses of multiple sclerosis-A systematic review and meta-analysis.

Johnen A, Landmeyer NC, Bürkner PC, Wiendl H, Meuth SG, Holling H.

Neurosci Biobehav Rev. 2017 Dec;83:568-578. doi: 10.1016/j.neubiorev.2017.09.005. Epub 2017 Sep 8. Review.

PMID:
28890199
44.

Cladribine - an old newcomer for pulsed immune reconstitution in MS.

Wiendl H.

Nat Rev Neurol. 2017 Oct;13(10):573-574. doi: 10.1038/nrneurol.2017.119. Epub 2017 Sep 8.

PMID:
28884753
45.

α4-integrin receptor desaturation and disease activity return after natalizumab cessation.

Derfuss T, Kovarik JM, Kappos L, Savelieva M, Chhabra R, Thakur A, Zhang Y, Wiendl H, Tomic D.

Neurol Neuroimmunol Neuroinflamm. 2017 Aug 25;4(5):e388. doi: 10.1212/NXI.0000000000000388. eCollection 2017 Sep.

46.

Anti-JCV serology during natalizumab treatment: Review and meta-analysis of 17 independent patient cohorts analyzing anti-John Cunningham polyoma virus sero-conversion rates under natalizumab treatment and differences between technical and biological sero-converters.

Schwab N, Schneider-Hohendorf T, Hoyt T, Gross CC, Meuth SG, Klotz L, Foley JF, Wiendl H.

Mult Scler. 2018 Apr;24(5):563-573. doi: 10.1177/1352458517728814. Epub 2017 Aug 29.

PMID:
28847222
47.

Can immune reprogramming with alemtuzumab induce permanent remission in multiple sclerosis?

Wiendl H, Bourdette D, Ciccarelli O.

Neurology. 2017 Sep 12;89(11):1098-1100. doi: 10.1212/WNL.0000000000004381. Epub 2017 Aug 23. No abstract available.

PMID:
28835406
48.

Can cognitive assessment really discriminate early stages of Alzheimer's and behavioural variant frontotemporal dementia at initial clinical presentation?

Reul S, Lohmann H, Wiendl H, Duning T, Johnen A.

Alzheimers Res Ther. 2017 Aug 9;9(1):61. doi: 10.1186/s13195-017-0287-1.

49.

Cortex Parcellation Associated Whole White Matter Parcellation in Individual Subjects.

Schiffler P, Tenberge JG, Wiendl H, Meuth SG.

Front Hum Neurosci. 2017 Jul 6;11:352. doi: 10.3389/fnhum.2017.00352. eCollection 2017.

50.

Gut-CNS-Axis as Possibility to Modulate Inflammatory Disease Activity-Implications for Multiple Sclerosis.

Fleck AK, Schuppan D, Wiendl H, Klotz L.

Int J Mol Sci. 2017 Jul 14;18(7). pii: E1526. doi: 10.3390/ijms18071526. Review.

Supplemental Content

Loading ...
Support Center